INTERMEZZO Drug Patent Profile

When do Intermezzo patents expire, and what generic alternatives are available?

Intermezzo is a drug marketed by Purdue Pharma and is included in one NDA. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has thirty-five patent family members in thirteen countries.

The generic ingredient in INTERMEZZO is zolpidem tartrate. There are thirty-three drug master file entries for this compound. Forty-three suppliers are listed for this compound. Additional details are available on the zolpidem tartrate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Intermezzo

A generic version of INTERMEZZO was approved as zolpidem tartrate by ACME LABS on April 23^rd, 2007.

Summary for INTERMEZZO

International Patents:	35
US Patents:	2
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	24
Clinical Trials:	1
Patent Applications:	124
Drug Prices:	Drug price information for INTERMEZZO
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for INTERMEZZO
What excipients (inactive ingredients) are in INTERMEZZO?	INTERMEZZO excipients list
DailyMed Link:	INTERMEZZO at DailyMed

See drug prices for INTERMEZZO

See drug sales revenues for INTERMEZZO

Recent Clinical Trials for INTERMEZZO

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Transcept Pharmaceuticals	Phase 3

See all INTERMEZZO clinical trials

Paragraph IV (Patent) Challenges for INTERMEZZO

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
INTERMEZZO	Sublingual Tablets	zolpidem tartrate	1.75 mg and 3.5 mg	022328	1	2012-04-10

US Patents and Regulatory Information for INTERMEZZO

INTERMEZZO is protected by two US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Purdue Pharma	INTERMEZZO	zolpidem tartrate	TABLET;SUBLINGUAL	022328-001	Nov 23, 2011		DISCN	Yes	No	7,658,945		Y
Purdue Pharma	INTERMEZZO	zolpidem tartrate	TABLET;SUBLINGUAL	022328-002	Nov 23, 2011		DISCN	Yes	No	8,242,131
Purdue Pharma	INTERMEZZO	zolpidem tartrate	TABLET;SUBLINGUAL	022328-001	Nov 23, 2011		DISCN	Yes	No	8,242,131
Purdue Pharma	INTERMEZZO	zolpidem tartrate	TABLET;SUBLINGUAL	022328-002	Nov 23, 2011		DISCN	Yes	No	7,658,945		Y

Expired US Patents for INTERMEZZO

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Purdue Pharma	INTERMEZZO	zolpidem tartrate	TABLET;SUBLINGUAL	022328-002	Nov 23, 2011	8,252,809
Purdue Pharma	INTERMEZZO	zolpidem tartrate	TABLET;SUBLINGUAL	022328-001	Nov 23, 2011	7,682,628
Purdue Pharma	INTERMEZZO	zolpidem tartrate	TABLET;SUBLINGUAL	022328-002	Nov 23, 2011	7,682,628
Purdue Pharma	INTERMEZZO	zolpidem tartrate	TABLET;SUBLINGUAL	022328-001	Nov 23, 2011	8,252,809

International Patents for INTERMEZZO

See the table below for patents covering INTERMEZZO around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	2005215782	Compositions for delivering hypnotic agents across the oral mucosa and methods of use thereof
Brazil	PI0507733	composição para a liberação de um agente hipnótico através da mucosa oral, e, método para tratar um distúrbio do sono em um paciente em necessidade deste
Canada	2556450	COMPOSITIONS PERMETTANT D'ADMINISTRER DES AGENTS HYPNOTIQUESDANS LA MUQUEUSE ORALE ET METHODES D'UTILISATION (COMPOSITIONS FOR DELIVERING HYPNOTIC AGENTS ACROSS THE ORAL MUCOSA AND METHODS OF USE THEREOF)
Canada	2816904	COMPOSITIONS PERMETTANT D'ADMINISTRER DES AGENTS HYPNOTIQUES DANS LA MUQUEUSE ORALE ET METHODES D'UTILISATION (COMPOSITIONS FOR DELIVERING HYPNOTIC AGENTS ACROSS THE ORAL MUCOSA AND METHODS OF USE THEREOF)
China	100548281

Supplementary Protection Certificates for INTERMEZZO

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2236132	C300714	Netherlands		PRODUCT NAME: ZOLPIDEM EN FARMACEUTISCH AANVAARDBARE ZOUTEN DAARVAN; NAT. REGISTRATION NO/DATE: RVG 108438 - 439 20130624; FIRST REGISTRATION: BE424286BE424295 2012180718
2236132	CA 2015 00004	Denmark		PRODUCT NAME: ZOLPIDEM OG FARMACEUTISK ACCEPTABLE SALTE HERAF, HERUNDER ZOLPIDEMTARTRAT; NAT. REG. NO/DATE: 47607 OG 47608 20120719; FIRST REG. NO/DATE: (B BE424286 OG BE424295 20120718
2236132	92636	Luxembourg		PRODUCT NAME: ZOLPIDEM ET SES SELS PHARMACEUTIQUEMENT ACCEPTABLES
2236132	122015000006	Germany		PRODUCT NAME: ZOLPIDEM UND PHARMAZEUTISCH VERTRAEGLICHE SALZE DAVON; NAT. REGISTRATION NO/DATE: 83439.00.00 83440.00.00 20120725 FIRST REGISTRATION: BELGIEN BE424286 BE424295 20120718
2236132	300714	Netherlands		PRODUCT NAME: ZOLPIDEM EN FARMACEUTISCH AANVAARDBARE ZOUTEN DAARVAN; NATIONAL REGISTRATION NO/DATE: RVG 108438 - 439 20160624; REGISTRATION NO/DATE: BE424286 20120718 BE424295 20120718

Last updated: July 25, 2026

Intermezzo (zolpidem tartrate) Market Dynamics and Financial Trajectory

Intermezzo (zolpidem tartrate) is a branded oral immediate-release sedative-hypnotic in the zolpidem franchise. Demand is constrained by class-wide regulatory tightening and competitive substitution among zolpidem products and generics. Commercial trajectory depends on (1) ongoing pharmacy-level substitution to lower-priced generics, (2) payer restrictions and step edits tied to safety labeling, and (3) loss or retention of market exclusivity/patent-protected product positioning, which in practice has tilted the branded share down over time.

Price and volume dynamics in this class are largely driven by generic penetration and reimbursement behavior rather than clinical differentiation. As a result, Intermezzo’s financial path has largely followed a “branded-to-generic value migration” pattern typical for older zolpidem assets.

---

What is Intermezzo and how does it fit the zolpidem market?

Intermezzo is zolpidem tartrate, an oral sedative-hypnotic used for insomnia. It belongs to the broader zolpidem category, which competes with other branded zolpidem products and with extensive generic availability.

Where does Intermezzo sit versus the rest of zolpidem?

Intermezzo is structurally part of the same therapeutic and substitution ecosystem as:

• branded zolpidem products (varies by historical availability and marketing)
• immediate-release zolpidem generics
• payer and PBM substitution policies that treat zolpidem products as interchangeable at the formulary level, subject to product-specific restrictions

Market implication: even when Intermezzo maintains label-based distinctness, payers often drive substitution at the cost and safety policy level, limiting branded net sales resilience.

---

How do FDA safety and labeling changes impact Intermezzo demand?

Zolpidem class exposure is shaped by evolving safety requirements and labeling constraints targeted at next-morning impairment, complex sleep-related behaviors, and dosing discipline. Those elements affect formulary policy and pharmacist/prescriber selection.

What demand levers are most sensitive in this class?

• Payer step edits: policies that require trial of lower-cost options or limit quantity/days supply.
• Prior authorization: less common for entrenched generics, more common for brand selection when utilization deviates from policy.
• Dose-conversion behavior: prescriber adherence to dosing limits and product selection can shift utilization within zolpidem brands, but typically does not reverse generic substitution.
• Conservative patient selection: higher-risk populations may be steered to alternatives.

Market implication: labeling tightening usually accelerates the decline of remaining branded share by increasing the probability that prescribers and pharmacies default to the cheapest acceptable option.

---

What patents and Orange Book status control Intermezzo’s branded exclusivity?

Intermezzo’s financial trajectory is highly sensitive to whether any remaining patent or exclusivity shield prevents generic entry, and whether any narrow composition, method, or formulation claims remain enforceable against ANDA filers.

Key question for market dynamics: does Intermezzo still have enforceable exclusivity?

Intermezzo has historically been subject to the classic post-launch lifecycle pattern: after the first waves of generic approvals and patent expirations, branded share compresses due to price differentials. When patent barriers fall, net sales typically drop sharply as wholesalers and pharmacies switch to generic zolpidem.

Market implication: if Intermezzo is currently off exclusivity, its branded revenue trajectory is primarily a function of contractual brand retention (if any), residual prescriber preference, and channel inventory effects.

---

When does Intermezzo lose exclusivity and how does that affect expected revenue?

For branded zolpidem products, the exclusivity timeline typically determines the size of the initial generic erosion and the speed of subsequent market normalization.

Typical financial pattern around generic entry (zoldipem class)

• Pre-entry: stable or slowly declining branded volume as physicians substitute selectively.
• First generic approvals: steep decline in brand unit share, with branded pricing pressure and higher rebates.
• Post-entry consolidation: stabilization at low brand share, sustained by contracts or physician preference niches.

Market implication: even without exact Orange Book dates in this dataset, the commercial behavior of zolpidem brands is strongly consistent with generic-driven revenue compression once exclusivity ends.

---

What generic entry risks exist for Intermezzo?

The generic entry risk for Intermezzo is driven by:

• the availability of zolpidem generics (immediate-release)
• ANDA filing volume for zolpidem-based products across strengths and dosing
• the likelihood that at least one ANDA can launch without infringing remaining brand-protecting claims, or after settlement allowing delayed entry

Practical risk framework for financial forecasting

• High risk if Intermezzo has limited remaining enforceable claims.
• Medium risk if brand has specific formulation or method-of-use barriers that slow ANDA launch or restrict labeling.
• Lower risk only if effective Orange Book listings with enforceable, non-expired claims cover the approved dosage form and the generic would need to design around.

Market implication: for older zolpidem assets, historical market behavior points to high probability of at least one low-cost generic capturing most incremental demand upon barrier removal.

---

How strong is the patent estate for Intermezzo compared with other zolpidem products?

A credible market view requires mapping:

• which Intermezzo-specific patents are listed in the Orange Book
• what claims (composition, formulation, method of use) they cover
• whether those patents have been asserted in litigation and what courts required for design-around

Competitive context inside zolpidem

Even where a brand maintains some patent coverage, the presence of multiple competing generic zolpidem products reduces branded leverage. Brand survival depends on whether the payer market views Intermezzo as meaningfully differentiated or as a substitutable immediate-release zolpidem option.

Market implication: without differentiated delivery technology or protected label uniqueness that payers accept as non-interchangeable, branded patent strength often translates into limited long-term financial lift.

---

What patent litigation affects Intermezzo and other zolpidem generics?

Litigation outcomes typically determine:

• whether a generic launch date is delayed
• whether the generic can launch “at risk”
• whether labeling carve-outs or design-around requirements preserve brand share temporarily

What litigation-driven outcomes change revenue?

• Automatic stay through Paragraph IV: delays can preserve brand share long enough for price support and contract retention.
• Settlement “pay-for-delay” or brand-favorable settlements: can extend brand exclusivity indirectly.
• Court findings of invalidity/non-infringement: accelerates generic erosion.

Market implication: for older zolpidem products, once major litigation ends, generic penetration generally continues and branded revenue declines.

---

How does Intermezzo compare with competing zolpidem generics on price and formulary access?

In the zolpidem class, price and formulary placement drive volume more than clinical superiority.

Formulary and PBM dynamics that usually matter most

• Generic step therapy favors the lowest-cost zolpidem.
• Quantity limits and therapy duration caps tend to apply uniformly across zolpidem products.
• Prior authorization is more likely to target non-preferred brands than generic options.

Market implication: Intermezzo financials are likely shaped by rebate strategy, contract status, and limited brand retention rather than sustained premium pricing.

---

What is Intermezzo’s FDA regulatory pathway status and how does it affect competition?

Intermezzo is an approved NDA product. Competitive pressure comes through ANDAs for generic zolpidem and through any future reformulation approvals.

How generic approval mechanics typically impact market speed

• ANDA approvals with bioequivalence often enable immediate substitution.
• If a generic needs a label change or design-around, substitution can be slower, but substitution usually occurs once the PBM policy accepts interchangeability.

Market implication: the faster bioequivalence and interchangeability are recognized, the faster Intermezzo branded net sales typically compress.

---

Who are the main commercial stakeholders in Intermezzo’s market?

Market actors include:

• the brand holder/labeler marketing Intermezzo
• generic manufacturers supplying ANDA products
• wholesalers distributing through channel
• payers and PBMs enforcing formulary rules
• pharmacy chains executing tiered copays and substitutable dispensing

Competitive landscape structure

• Brand position: usually niche and contract-dependent after generic availability.
• Generic position: supply is typically broad for zolpidem immediate-release strengths, enabling competitive pricing.

Market implication: financial trajectory tends to correlate with generic pricing pressure and rebate intensity.

---

What financial trajectory should investors model for Intermezzo?

A high-confidence financial framework for a branded zolpidem product looks like this:

Revenue model shape

• Revenue share compression: declining branded units as generic share rises.
• Price erosion: lower net price driven by rebate pressure and competitive shelf pricing.
• Stabilization: after the largest generic entries, the brand often stabilizes at low single-digit to low-teens share depending on contracts and payer behavior.

Cost structure and margin effects

• Marketing and contracting costs typically rise as brand volume declines, compressing operating margin.
• Distribution and trade spend adjust to keep the brand in preferred tiers where possible.

Market implication: absent a new differentiation or enforceable exclusivity shock, Intermezzo’s branded net sales generally trend down with limited upside.

---

Key Takeaways

• Intermezzo’s market dynamics are dominated by generic substitution economics in the zolpidem franchise and payer-driven formulary behavior.
• FDA safety labeling and dose discipline policies increase conservative prescribing and facilitate substitution to lower-cost options.
• Financial trajectory generally follows the branded-to-generic compression curve, with contract retention and rebate strategy determining residual brand share.
• Exclusivity and Paragraph IV-related outcomes, if any remaining, are the main levers that can delay erosion; once barriers are removed, revenue decline accelerates.
• For forecasting and valuation, model unit share loss, net price compression, and trade/rebate escalation rather than expecting durable premium differentiation.

---

FAQs

1) Why do zolpidem brands like Intermezzo lose market share even with consistent efficacy?

Because payers and pharmacies treat zolpidem products as substitutable immediate-release options once generics are available, and the economic incentive favors the lowest-cost equivalent.

2) Do safety warnings change prescribing behavior enough to shift between brands?

They can influence patient selection and prescribing discipline, but they typically do not prevent substitution across zolpidem immediate-release products once generic coverage is established.

3) What usually happens to Intermezzo net price after generic launches?

Net price typically falls as branded rebates rise, wholesalers push lower-priced supply, and PBM tiering favors generic utilization.

4) Can a settlement delay generics and support Intermezzo sales?

Yes, settlements can delay entry or limit launch parameters, which can preserve branded share temporarily; the effect depends on the specific settlement terms and remaining enforceable claims.

5) What market signals best predict Intermezzo revenue direction?

Generic market penetration metrics for zolpidem immediate-release, PBM formulary tier changes, and changes in branded rebate intensity and net-to-gross.

---

References

1. U.S. Food and Drug Administration. Approved Drug Products: Zolpidem products (Orange Book). U.S. FDA.
2. U.S. Food and Drug Administration. Drug Safety Communications and labeling updates related to zolpidem. U.S. FDA.
3. FDA. ANDA approval framework and bioequivalence requirements (regulatory guidance and standards). U.S. FDA.